1H HRMAS NMR derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples

Biomarker Insights

Volumn 6, Issue , 2011, Pages 39-47

  Stenman, Katarina ^a   Stattin, Pär ^c   Stenlund, Hans ^d   Riklund, Katrine ^a   Gröbner, Gerhard ^d   Bergh, Anders ^b  

^a Diagnostic Radiology   (Sweden)

^b Pathology   (Sweden)

^c Surgical and Perioperative Sciences   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Gleason score; HRMAS; Inositol; Ki67; MRSI; Prostate cancer

Indexed keywords

CHOLINE; CITRIC ACID; CREATINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; KI 67 ANTIGEN; PHOSPHORYLCHOLINE; SCYLLO INOSITOL; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC TEST; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METABOLITE; MOLECULAR IMAGING; PROSTATE CANCER; PROTON HIGH RESOLUTION MAGIC ANGLE SPINNING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL;

EID: 79952937101     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S6794     Document Type: Article

References (47)

1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100-10
2. Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer. CA Cancer J Clin. 2010;60:70-98
3. Chrouser KL, Lieber MM. Extended and saturation needle biopsy for the diagnosis of prostate cancer. Curr Urol Rep. 2004;5(3):226-30
4. Fleshner N, Klotz L. Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology. 2002;60:93-7
5. Baccala AA, Moussa AS, Elbary AA, et al.Risk factors and predictors of prostate cancer in men with negative repeat saturation biopsy. Uro Today Int J. 2010;3(1).
6. Tessem MB, Selnaes KM, Sjursen W, et al. Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res. 2010;9(7): 3664-70
7. Santos CF, Kurhanewicz J, Tabatabai ZL, et al. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. In press.
8. Levin YS, Mark J. Albers MJ, et al. Methods for metabolic evaluation of prostate cancer cells using proton and 13C HR-MAS spectroscopy and [3-13C] pyruvate as a metabolic substrate. Magn Reson Med. 2009;62: 1091-8
9. Shukla-Dave A, Hricak H, Ishill N, et al. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res. 2009;15(11):3842-9
10. Lange T, Schulte RF, Boesiger P. Quantitative J-resolved prostate spectroscopy using two-dimensional prior-knowledge fitting. Magn Reson Med. 2008;59(5):966-72
11. Cheng LL, Lean CL, Bogdanova A, et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med. 1996;36:653-8
12. Sitter B, Sonnewald U, Spraul M, Fjösne H, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002; 15(5):327-37
13. Beckonert B, Coen M, Keun HC, et al. High-resolution magic- angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nature Protocols. 2010;5:1019-32
14. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58-64
15. Swanson MG, Vigneron DB, Tabatabai ZL, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI targeted post-surgical prostate tissues. Magn Reson Med. 2003;50(5):944-54
16. Josefsson A, Wikström P, Granfors T, et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol. 2005; 48(4):577-83
17. Halin S, Hammarsten P, Adamo H, Wikstrom P, Bergh A. Tumor indicating normal tissue (TINT) could be a novel source of diagnostic and prognostic markers for prostate cancer. Expert Opinion on Medical Diagnostics, 2011,5(01):37-47
18. Meiboom S, Gill D. Modified spin-echo method for measuring nuclear relaxation times, Rev. Sci Instrum. 1958;29:688-91
19. Jordan KW, He W, Halpern EF, Wu C-L, Cheng LL. Evaluation of tissue metabolites with high resolution magic angle spinning MR spectroscopy human prostate samples after three-year storage at -80 °C. Biomarker Insights. 2007;2:147-54
20. Stenman K, Hauksson JB, Gröbner G, Stattin P, Bergh A, Riklund K. Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy. MAGMA. 2009;22(6):327-31
21. Stenman K, Surowiec I, Antti H, et al. Detection of local prostate metabolites by HRMAS NMR spectroscopy: A comparative study of human and rat prostate tissues. Magnetic Resonance Insights. 2010;4:27-41
22. Van Asten J, Cuijpers V, Hulsbergen-van de Kaa C, et al. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. Magn Reson Mater Phy. 2008;21:435-42
23. Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006;55(6):1257-64
24. Swindle P, McCredie S, Russell P, et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology. 2003;228: 144-51
25. Singh KK, Desouki MM, Franklin RB, Costello LC. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer. 2006;5:14.
26. McLean MA, Barrett T, Gnanapragasam VJ, et al. Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magn Reson Med. In print. 2010.
27. Swindle P, Ramadan S, Stanwell P, McCredie S, Russell P, Mountford C. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. Magn Reson Mater Phy. 2008;21:423-34
28. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006;19:30-40
29. Cheng LL, Burns MA, Taylor JL, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance. Cancer Res. 2005;65: 3030-4
30. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16:451-63
31. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: Role of Imaging AJR. 2009;192:1455-70
32. Zakian KL, Sircar K, Hricak H, Chen H-N, Shukla-Dave A, Eberhardt S. Correlation of proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy. Radiology. 2005;234:804-14
33. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate. 2009;69(13):1470-9
34. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89(6):538-42
35. Patricia Beemster P, Groenen P, Steegers-Theunissen R. Involvement of inositol in reproduction. Nutrition Reviews. 2002;60(3):80-7
36. Lewin LM, Yannai Y, Sulimovici S, Kraicer PF. Studies on the metabolic role of myo-inositol. Distribution of radioactive myo-inositol in the male rat. Biochem J. 1976;156:375-80
37. Mann T. Secretory function of the prostate, seminal vesicle and other male accessory organs of reproduction. J Reprod Fert. 1974;37:179-88
38. Seelan RS, Lakshmanan J, Casanova MF, Parthasarathy RN. Identification of myo-inositol-3-phosphate synthase isoforms. Characterization, expression, and putative role of a 16-kDa ãc isoform. JBC. 2009;284:9443-57
39. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr. 2003;133(11 Suppl 1): 3778S-84.
40. Bacić I, Druzijanić N, Karlo R, Skifić I, Jagić S. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J Exp Clin Cancer Res. 2010;29:12.
41. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein- E2F complexes. Carcinogenesis. 2003;24(3):555-63
42. Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C, Agarwal R. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate. Induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res. 2004;10:244.
43. Roy S, Gu M, Ramasamy K, et al. p21/Cip1 and p27/Kip1 are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res. 2009;69(3):1166-73
44. Gu M, Roy S, Raina K, Agarwal C, Agarwal R. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res. 2009;69(24):9465-72
45. Vasdev N, Chio J, van Oosten EM, et al. Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chem Commun (Camb). 2009;(37):5527-9
46. Pimlott SL, Sutherland A. Molecular tracers for the PET and SPECT imaging of disease. Chem Soc Rev. 2011;40(1):149-62
47. Duarte IF, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumors? Virchows Arch. 2010;457:715-25